Debt-free Balance SheetNo reported debt meaningfully lowers financial risk and interest burden, giving management flexibility to prioritize R&D and clinical programs. This structural strength extends the company's runway compared with leveraged peers and supports downside resilience while it pursues commercialization or partnerships.

Very High Gross MarginsNear-100% gross margins indicate favorable product or IP economics common in proprietary biologics and platform tech. If revenue scales or licensing deals materialize, operating leverage could quickly translate high contribution margins into improved operating profitability over time, supporting sustainable margins.

Proprietary Cell-engineering PipelineA focused proprietary platform in engineered immune cells creates a durable competitive moat and multiple commercialization pathways (partners, licenses, or direct sales). Platform IP and pipeline optionality align with long-term structural growth in immuno-oncology and could unlock non-dilutive partnerships or milestone revenue.

Bears Say

Shrinking And Volatile RevenueMaterial and persistent revenue decline undermines scalability: with revenues falling ~45% in 2025 and volatility across years, the company lacks stable top-line traction. This reduces predictability for R&D investment returns and heightens the need for external funding or transformative partnerships to restore growth.

Persistent Operating Cash BurnConsistent negative operating cash flow means the business cannot self-fund its development cycle and remains dependent on external financing. Even with no debt, ongoing cash burn will erode equity, create dilution risk, and constrain strategic choices absent durable revenue or non-dilutive partner financing.

Large Net Losses And Negative MarginsVery large net losses and dramatically negative margins indicate failure to convert high gross margins into operating profitability. Persistent losses reduce retained capital and make multi-year reinvestment dependent on financings, limiting the firm's ability to demonstrate durable returns for shareholders in the near term.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥120.00 and its highest was ¥214.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.58B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is May 19, 2026 which is in 72 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Feb 13, 2026. The company reported -¥4.36 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.36.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥4.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.938%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.